Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Not Confirmed
Not Confirmed
10-11 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Industry Trade Show
Not Confirmed
10-11 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
02 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/02/3054025/0/en/Helsinn-Group-submits-a-new-formulation-of-AKYNZEO-to-the-European-Medicines-Agency-EMA.html
26 Jun 2024
// PHARMABIZ
24 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/24/2902897/0/en/Helsinn-Group-announces-AKYNZEO-fosnetupitant-palonosetron-injection-is-now-available-in-a-ready-to-use-vial-in-the-US.html
28 May 2024
// PHARMACEUTICAL TECHNOLOGY
https://www.pharmaceutical-technology.com/news/helsinn-angelini-distribution-deal/
27 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/27/2888406/0/en/Helsinn-and-Angelini-Pharma-sign-a-partnership-agreement-renewal-to-commercialize-AULIN-and-MESULID-in-Bulgaria-Czech-Republic-Hungary-Poland-Romania-and-Slovak-Republic.html
10 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/10/2757386/0/en/Helsinn-closes-financing-agreement-with-BancaStato-to-support-business-objectives-and-growth.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10877
Submission : 1994-04-11
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-348 - Rev 04
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1255
Status : Valid
Registration Number : 221MF10103
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2009-05-27
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18826
Submission : 2005-09-30
Status : Active
Type : II
Certificate Number : R0-CEP 2021-328 - Rev 00
Issue Date : 2022-09-05
Type : Chemical
Substance Number : 2445
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31323
Submission : 2017-03-31
Status : Active
Type : II
Registration Number : 302MF10154
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2020-12-15
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-09
Pay. Date : 2012-12-14
DMF Number : 19918
Submission : 2006-10-30
Status : Active
Type : II
Certificate Number : R1-CEP 2004-281 - Rev 01
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1019
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16063
Submission : 2002-07-19
Status : Active
Type : II
Registration Number : 220MF10072
Registrant's Address : Via Industria, 24 6710 Biasca Switzerland
Initial Date of Registration : 2008-03-14
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30961
Submission : 2016-11-16
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31120
Submission : 2016-11-16
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19498
Submission : 2006-06-01
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26715
Submission : 2013-07-19
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2010-377 - Rev 02
Issue Date : 2022-03-01
Type : Chemical
Substance Number : 1548
Status : Valid
Registrant Name : JW Pharmaceutical Co., Ltd.
Registration Date : 2021-07-30
Registration Number : 20210730-209-J-1083
Manufacturer Name : Helsinn Advanced Synthesis SA (Helsinn/HAS)
Manufacturer Address : Via Industria 24, 6710 Biasca, Switzerland
Details:
Akynzeo (netupitant and palonosetron) is the first and only 5-HT3 and NK1 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting in emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 02, 2025
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Submits New AKYNZEO Formulation to European Medicines Agency
Details : Akynzeo (netupitant and palonosetron) is the first and only 5-HT3 and NK1 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting in emetogenic chemotherapy.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2025
Details:
Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Lead Product(s): Fosnetupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Fosnetupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2025
Details:
Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fosnetupitant,Netupitant,Palonosetron
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2025
Lead Product(s) : Fosnetupitant,Netupitant,Palonosetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosnetupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2025
Details:
The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Esteve Quimica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2025
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Esteve Quimica
Deal Size : Undisclosed
Deal Type : Partnership
Helsinn Group & ESTEVE Renew Partnership for AKYNZEO® and ALOXI® in Germany
Details : The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 08, 2025
Details:
Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2024
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Group launches Akynzeo injection in US market
Details : Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2024
Details:
The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Lead Product(s): Netupitant,Dexamethasone,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Chugai Pharma Europe
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2024
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Chugai Pharma Europe
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland
Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 12, 2024
Details:
Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Lead Product(s): Nimesulide,Inapplicable
Therapeutic Area: Neurology Brand Name: Mesulid
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Angelini Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 24, 2024
Lead Product(s) : Nimesulide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe
Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Product Name : Mesulid
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 24, 2024
Details:
Netupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Simon Williamson Clinic
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Simon Williamson Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
Details : Netupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023
Details:
Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer che...
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2023
Details:
Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Brand Name: Akynzeo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Immedica Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 24, 2023
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Immedica Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogeni...
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 24, 2023
Inspections and registrations
District Decision : No Action Indicated
Inspection End Date : 2014-04-04
City : Pazzallo
State :
Country/Area : Switzerland
Zip :
District : ORA
Center : CDER
Project Area : Bioresearch Monitoring
District Decision : No Action Indicated
Inspection End Date : 2014-04-04
District Decision : No Action Indicated
Inspection End Date : 2014-02-21
City : Dublin
State :
Country/Area : Ireland
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2014-02-21
District Decision : Voluntary Action Indicated
Inspection End Date : 2010-05-27
City : Dublin
State :
Country/Area : Ireland
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2010-05-27
ABOUT THIS PAGE
Helsinn Advanced Synthesis is a supplier offers 19 products (APIs, Excipients or Intermediates).
Find a price of Pyridostigmine bulk with CEP, JDMF offered by Helsinn Advanced Synthesis
Find a price of Adapalene bulk with DMF, CEP offered by Helsinn Advanced Synthesis
Find a price of Fosnetupitant Chloride bulk with DMF, JDMF offered by Helsinn Advanced Synthesis
Find a price of Isotretinoin bulk with DMF, CEP offered by Helsinn Advanced Synthesis
Find a price of Palonosetron bulk with DMF, JDMF offered by Helsinn Advanced Synthesis
Find a price of Anamorelin HCl bulk with DMF offered by Helsinn Advanced Synthesis
Find a price of Dantrolene bulk with DMF offered by Helsinn Advanced Synthesis
Find a price of Netupitant bulk with DMF offered by Helsinn Advanced Synthesis
Find a price of Nimesulide bulk with CEP offered by Helsinn Advanced Synthesis
Find a price of Trifarotene bulk with DMF offered by Helsinn Advanced Synthesis
Find a price of Chlorzoxazone bulk offered by Helsinn Advanced Synthesis
Find a price of Guanabenz bulk offered by Helsinn Advanced Synthesis
Find a price of Melatonin bulk offered by Helsinn Advanced Synthesis
Find a price of Meso-2,3-Dimercaptosuccinic Acid bulk offered by Helsinn Advanced Synthesis
Find a price of Modafinil bulk offered by Helsinn Advanced Synthesis
Find a price of Sodium Benzoate bulk offered by Helsinn Advanced Synthesis
Find a price of Tramadol Hydrochloride bulk offered by Helsinn Advanced Synthesis
Find a price of Trospium Chloride bulk offered by Helsinn Advanced Synthesis
Find a price of Bosentan Hydrate bulk offered by Helsinn Advanced Synthesis